Table 1.

Characteristics of the included studies. ELISA was used for determining calprotectin levels in all studies.

StudyYrStudy DesignStudy PopulationnAge, YrsSex, M/FDiagnostic CriteriaInclusion/exclusion CriteriaDisease Duration ReportedWide DAS RangeTreatment ReportedSample Controls Reference Values
Berntzen, et al241988CSInpatients47NRNRARA 1958YNNRNPlasmaYY
Berntzen, et al251991CSIn/outpatients41Med 5911/30ARA 1958YYNRYPlasma, SFYY
Brun, et al261992CSNR43Med 574/39ARA 1958YYNRYPlasmaYY
Brun, et al271994CSInpatients70Mean 6022/48ARA 1958YYNRYPlasmaYY
Burmeister, et al281995CSNR11NRNRARA, NRNNNRNSFYNA
Madland, et al292002Longitudinal 5 yrsInpatients56Med 6318/38ACR 1987NYNRYPlasmaNY
Drynda, et al302004CSNR23NRNRACR 1987NNNNPlasma, SFYN
Longitudinal 3 mosBiologic cohort40Mean 515/35ACR 1987NNN, DAS 28 6.26 ± 0.2NPlasmaYN
De Rycke, et al312005CSNR40Med 4512/28ACR 1987NYYYserum, SFYN
Sunahori, et al322006CSInpatients17Mean 633/14ACR 1987NNNYserum, SFYN
Hammer, et al332007CSEarly RA cohort145Mean 6035/110ACR 1987YYYYPlasmaNY
De Seny, et al342008CSNR34Med 5512/22ACR 1987NYN, 86% DAS28 > 5.1YPlasmaYY
Hammer, et al352008Longitudinal 1 yrNR61Mean 5814/47ACR 1987NYN, DAS28 4 ± 1.4YPlasmaNY
Hammer, et al362010Longitudinal 10 yrsEarly RA cohort124Mean 5130/94ACR 1987YYNYPlasmaNY
Andrés Cerezo, et al372011Longitudinal 3 mosEarly RA cohort43Mean 5113/30ACR/EULAR 2010YYN, DAS28 5.3 ± 1.5YSerumYN
Hammer, et al382011Longitudinal 1 yrBiologic cohort20Med 535/15ACR 1987NYYYPlasmaNY
García-Arias, et al392013CSSingle-center cohort60Mean 5815/45ACR 1987YYYYSerumNY
Longitudinal 6 mosBiologic cohort20Mean 642/18ACR 1987YYNYSerumNY
Choi, et al402013Longitudinal 4–6 mosBiologic cohorts170Med 5732/138ACR 1987YNNYSerumNY
  • DAS: Disease Activity Score; CS: cross-sectional; NR: not reported; ARA: American Rheumatism Association; Y: yes; N: no; Med: median; SF: synovial fluid; NA: not applicable; ACR: American College of Rheumatology; DAS28: 28-joint DAS; EULAR: European League Against Rheumatism; RA: rheumatoid arthritis.